Neurocrine Biosciences has signed a licence and collaboration agreement valued at more than $1.7bn with Xenon Pharmaceuticals to develop epilepsy treatments.
As part of the deal, Neurocrine receives an exclusive licence to a selective Nav1.6 sodium channel inhibitor candidate, XEN901. The drug is being developed to potentially treat SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other epilepsies.
Go deeper with GlobalData
Neurocrine also gets a licence to exclusively develop pre-clinical compounds, including selective Nav1.6 and dual Nav1.2 / 1.6 inhibitors.
Furthermore, the agreement includes a multi-year research alliance to discover and develop additional Nav1.6 and Nav1.2 / 1.6 inhibitors.
Neurocrine Biosciences CEO Kevin Gorman said: “The agreement with Xenon strengthens Neurocrine Biosciences’ diverse and growing pipeline and reinforces our long-term commitment of becoming a leading neuroscience-focused biopharmaceutical company.”
Neurocrine will bear developments costs of all programmes covered under the partnership. The company will pay $50m to Xenon, including an upfront cash payment of $30m and an equity investment of $20m.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataFurthermore, Neurocrine will pay up to $25m upon the US Food and Drug Administration (FDA) acceptance of XEN901’s investigational new drug (IND) application. Of this payment, 55% will be paid as an equity investment.
The company expects to file an IND next year for the clinical trial of XEN901 in SCN8A-DEE patients.
Xenon will also gain up to $1.7bn in development, regulatory and commercial milestones associated with XEN901 and additional licenced Nav1.6 or Nav1.2 / 1.6 inhibitors, as well as sales royalties.
The company holds an option to fund 50% of the US development costs of a product candidate and will, in turn, receive royalties for XEN901 sales in the country.
Xenon Pharmaceuticals CEO Dr Simon Pimstone said: “Importantly, this collaboration represents a significant investment in XEN901 and Xenon’s earlier-stage Nav1.6 and Nav1.2 / 1.6 inhibitor programs and allows for a broader development of these promising compounds than we could accomplish independently.
“Furthermore, the additional capital from this transaction will support our efforts to advance and expand our proprietary pipeline.”
